



NDA 018817/S-035

SUPPLEMENT APPROVAL

Pfizer Inc.
Attention: Nataly Zarate
Sr. Manager, Pfizer Global Regulatory Affairs
235 East 42nd Street
New York, NY 10017-5755

Dear Nataly Zarate:

Please refer to your Supplemental New Drug Application (sNDA) dated and received May 27, 2021, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Calan (verapamil hydrochloride) tablets, 80 mg and 120 mg.

This Prior Approval supplemental new drug application provides for updated USPI to indicate functionality of existing score on Calan (verapamil hydrochloride) 80 mg tablets and to include proposed text regarding storage and handling of the split tablets based on information submitted and approved in S-030.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Elizabeth Eydelman, MPH, Regulatory Business Process Manager, at (301) 796 - 5071.

Sincerely,

{See appended electronic signature page}

David Lewis, PhD
Branch Chief, Branch 2
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure:

Content of Labeling



David
Lewis

Digitally signed by David Lewis
Date: 11/19/2021 09:39:09AM
GUID: 508da72000029f287fa31e664741b577